AccessibilityHelpAbout Us
ResMed logo

ResMed(ASX) RMD

Market CapA$45.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)+4,346%
5 Year-16%
1 Year-21%
1 Month+2%
A$31.66
-0.66%
-0.21Today
ResMed last closing stock price
MetricPriceDate
Last closeAUD 31.872026-09-18
ResMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.15%AUD 30.312026-09-11
1 month+1.98%AUD 31.252026-08-19
3 month+19.81%AUD 26.602026-06-19
Year to date-10.6%AUD 35.652025-12-31
1 year-21.33%AUD 40.512025-09-18
3 year+44.49%AUD 22.062023-09-19
5 year-15.63%AUD 37.772021-09-17
Since inception+4,345.91%AUD 0.721999-11-26

ResMed Financials at a Glance

Market Cap

A$45.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.63B

Net Income (TTM)

$1.52B

EPS (TTM)

A$1.54

P/E Ratio

20.72

Dividend

A$0.35

Beta (Volatility)

-0.01 (Low)

Price

A$31.66

Volume

911,163

Open

A$31.55

Previous Close

A$31.66

Daily Range

A$31.50 - A$31.76

52-Week Range

A$25.50 - A$43.29

Estimated Earnings Date

Oct 22, 2026

RMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ResMed

ResMed Inc. is a leading global company that designs, manufactures, and markets innovative medical devices and cloud-based software solutions for the healthcare industry. The company specializes in Sleep and Respiratory Care, providing comprehensive solutions for various respiratory disorders.

Products and Services
  • Advanced ventilation devices and diagnostic tools for respiratory disorders
  • Cloud-based software platforms for remote patient monitoring and therapy management
  • Business management software for home medical equipment providers
Growth Outlook
  • Projected revenue growth driven by increasing demand for sleep apnea solutions
  • Expansion into new markets, enhancing global distribution capabilities
  • Investment in R&D to innovate and improve product offerings
Financial Highlights
  • Recent quarterly revenue of USD 1.43 billion, reflecting strong market demand
  • Net income of USD 374 million, showcasing robust profitability
  • TTM gross profit margin of 61.2%, indicating efficient cost management
ResMed Inc. operates in a growing sector, with a focus on enhancing patient care through innovative technology. The company's diverse product range and commitment to research and development position it well for future growth. Recent financial performance highlights a strong revenue base and profitability, making it an attractive option for investors interested in the healthcare technology space. The ongoing expansion into new markets and continuous investment in product innovation further support a positive growth trajectory.
AI Generated • Sep 17, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

11,370

CEO

Mick Farrell, MBA

Website

www.resmed.com

Headquarters

San Diego, CA 92123, US

RMD Financials

Key Financial Metrics (TTM)

Gross Margin

61.16%

Operating Margin

33.48%

Net Income Margin

26.94%

Return on Equity

23.88%

Return on Capital

26.49%

Return on Assets

16.99%

Earnings Yield

4.83%

Dividend Yield

1.11%

Payout Ratio

40.19%

Stock Overview

Market Cap

A$45.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.44B

Volume

911.16K

Avg. Volume

1.80M

Financials (TTM)

Gross Profit

$3.40B

Operating Income

$1.90B

EBITDA

$2.14B

Operating Cash Flow

$1.80B

Capital Expenditure

-$155.41M

Free Cash Flow

$1.64B

Cash & ST Invst.

$1.47B

Total Debt

$825.56M

ResMed Performance Analysis

ResMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 6,277,637,76527.2%
20242024-06-30USD 7,149,032,78113.9%
20252025-06-30USD 7,946,391,08011.2%
20262026-06-30USD 8,343,056,3045.0%
ResMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-0.9%
Q22025-12-318.3%
Q32026-03-31-1.9%
Q42026-06-300.7%
ResMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 0.9023.8%
20242024-06-30USD 1.0616.7%
20252025-06-30USD 1.4739.0%
20262026-06-30USD 1.544.9%
ResMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30800.8%
Q22025-12-31-88.6%
Q32026-03-31N/A
Q42026-06-30-3.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$1.43B

+6.0%

Gross Profit

$830.39M

+1.3%

Gross Margin

58.12%

N/A

Market Cap

A$45.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$4.04M

N/A

Employees

11,370

N/A

Net Income

$374.27M

-1.4%

EBITDA

$497.28M

-6.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$1.47B

+21.4%

Total Debt

$825.56M

-3.1%

Accounts Receivable

$1.04B

+4.6%

Inventory

$945.40M

+1.9%

Long Term Debt

$536.60M

-33.9%

Short Term Debt

$289.09M

+615.5%

Return on Assets

16.99%

N/A

Return on Invested Capital

25.00%

N/A

Free Cash Flow

$385.75M

-23.6%

Operating Cash Flow

$435.70M

-19.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SIG.AXSigma Healthcare Limited
A$2.53-0.78%
FPH.AXFisher & Paykel Healthcare Corporation Limited
A$35.74+1.51%
SHL.AXSonic Healthcare Limited
A$19.47+1.20%
CSL.AXCSL Limited
A$178.30+1.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About RMD

What is the current price of ResMed?

ResMed is trading at A$31.66 per share.

What is the 52-week range for ResMed?

Over the past 52 weeks, ResMed has traded between A$25.50 and A$43.29.

How much debt does ResMed have?

As of the most recent reporting period, ResMed reported total debt of $1.19B.

How much cash does ResMed have on hand?

ResMed reported $2.12B in cash and cash equivalents in its most recent financial results.

What is ResMed’s dividend yield?

ResMed currently has a dividend yield of 1.11%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services